Y-mAbs Therapeutics, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD from Q4 2017 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Y-mAbs Therapeutics, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and growth rate from Q4 2017 to Q4 2023.
  • Y-mAbs Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending December 31, 2023 was $83.2M, a 3.29% decline year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $83.2M -$2.84M -3.29% Dec 31, 2023 10-K 2024-02-29
Q4 2022 $86.1M -$2.9M -3.26% Dec 31, 2022 10-K 2024-02-29
Q4 2021 $89M +$13.3M +17.5% Dec 31, 2021 10-K 2023-03-30
Q4 2020 $75.7M +$24.1M +46.6% Dec 31, 2020 10-K 2022-03-01
Q4 2019 $51.6M +$26.4M +104% Dec 31, 2019 10-K 2021-03-01
Q4 2018 $25.3M +$14.4M +133% Dec 31, 2018 10-K 2020-03-12
Q4 2017 $10.8M Dec 31, 2017 10-K 2019-03-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.